Download presentation
Presentation is loading. Please wait.
1
Psychopharmacology of ADHD
Psychopharmacology of ADHD Scott Carroll, MD Founder – Ayni Neuroscience Institute Author of Don’t Settle: How to Marry the Man You Were Meant For
2
DIAGNOSIS AND TREATMENT OPTIONS
Written evaluations (Connor/Vanderbuilt) from teachers, parents and pt (10yo+) to make diagnosis No diagnosis by medication trial!!! (IT except) Educate parents/pt about the dxn and txt options Risk/benefit analysis, not everyone needs txt Get baseline ht, wt, vitals and labs (EKG ?) Repeat evals yearly and with dose increases
3
ADHD – Neurochemistry Dopamine depletion hypothesis (Shaywitz et al 1977) lower levels of homovanillic acid (HVA), dopamine metabolite in CSF of ADHD compared to controls Executive function impairments caused by hypofrontality secondary to structural, biochemical changes in prefrontal cortex Genetic studies showing associations with DAT1, DRD4 - 7 repeat alleles Norepinephrine clearly involved but poorly studied Serotonin - weak, inconsistent evidence of involvement GABA - no evidence of involvement N=54 children with ADHD and 18 psychiatric controls Spect at rest and during visual CPT Limitations: -qualitative analysis -Comorbid conditions and/or developmental/neurological complications not controlled for -lack of control group matched for age or IQ
4
ADHD - Medication Treatment
The psychostimulants are the most effective Non-stimulants are mildly to moderately effective Large individual differences in doses and to specific medications (25/50/25 rule of thumb) Start with methylphenidate (no SCD, except w/Sz) Hyperactive may require higher doses than inattention
5
ADHD Medications Classes of Medication
psychostimulants – regular, sustained-release -adrenergic agents (clonidine and guanfacine) atypical antidepressants (bupropion, mirtazapine) NE-specific reuptake inhibitors (atomoxetine) tricyclic antidepressants (no longer used) dopaminergic agents (modafinil but risk of SJS)
6
ADHD - The Psychostimulants
methylphenidate (Ritalin) d-amphetamine (Dexedrine) amphetamine salt mixture (Adderall) amphetamines increase risk of sudden cardiac death with structural cardiac abnormalities and other serious heart problems, esp. Adderall Starting with long acting formulation is better
7
ADHD - Psychostimulants
Methylphenidate (Ritalin) – 5, 10, 20mg Dosage/Schedule mg/kg/dose ( mg/dose) mg/kg/day ( mg/day) mg usual starting dose
8
ADHD - Psychostimulants
Methylphenidate Advantages clear positive effects on inattention, distractibility, hyperactivity short duration of action (3 - 4 hours) allows individual fine-tuning doesn’t show up in standard urine drug test can increase HR/BP, no clear risk of SCD
9
ADHD - Psychostimulants
Methylphenidate Disadvantages short duration requires bid or tid dosing abuse potential FDA approval for 6yo and up slightly lowers seizure threshold
10
ADHD - Psychostimulants
Methylphenidate (Ritalin) More common side effects loss of appetite weight loss insomnia irritability behavioral rebound GI upset
11
ADHD - Psychostimulants
Methylphenidate (Ritalin) Less common side effects tics (likely increased rather than caused) growth retardation (due to low appetite) elevated heart rate and blood pressure psychosis depression and dysphoria hyperfocus decreased seizure threshold
12
ADHD - Psychostimulants
Methylphenidate – Other Preparations Ritalin LA – 10, 20, 30, 40 mg; 4-8 hour duration Methylin – 5, 10, 20 mg; 5, 10 mg chewable; 5 mg/5ml, 10mg/5ml solutions Methylin ER – 10, 20 mg; 4-8 hour duration Focalin – 2.5, 5, 10 mg dex-methylphenidate (half dose) Focalin XR – 5, 10, 15, 20, 30 mg; hour duration
13
ADHD - Psychostimulants
Methylphenidate – Other Preparations Concerta – 18, 27, 36, 48, 54 and 72 mg tablets; 14 hour duration, allows once a day dosing for most patients Metadate-ER – 10, 20 mg; 4-8 hour duration Metadate-CD – 10, 20, 30 mg; 8-12 hour duration Daytrana - methylphenidate patch (pediatric absorption?) Quillivant XR – liquid, 12 hour duration (in theory)
14
ADHD - Psychostimulants
Concerta 18, 27, 36, 54, 72 mg no noon (at school) dose usual starting dose 18 mg do not crush or chew
15
ADHD - Psychostimulants
Methylphenidate - Metadate CD 10, 20, 30 mg SR; ~ 8-12 hour duration may open capsule and sprinkle on/in non-chewed food immediately prior to administration; do not crush or chew Difucaps
16
ADHD - Psychostimulants
D-amphetamine (Dexedrine) 5, 10 mg; 5, 10, 15 mg spansule Dosage/Schedule mg/kg/dose ( mg/dose) mg/kg/day ( mg/day) mg usual starting dose
17
ADHD - Psychostimulants
D-amphetamine (Dexedrine) Advantages clear positive effects on inattention, distractibility, and hyperactivity longer duration of action (6 - 8 hours) long-acting spansules available (6-10 hours) FDA approved for 3 years old and up preferable in patients with seizure disorders
18
ADHD - Psychostimulants
D-amphetamine (Dexedrine) Disadvantages street reputation/diversion potential abuse potential longer action may complicate schedule
19
ADHD - Psychostimulants
D-amphetamine (Dexedrine) Side effects as with methylphenidate (Ritalin), except for d-amphetamine’s mild antiepileptic effect
20
ADHD - Psychostimulants
Other Amphetamine Preparations Adderall – 5, 7.5, 10, 12.5, 15, 20, 30 mg dextroamphetamine saccharate + amphetamine aspartate + dextroamphetamine sulphate + amphetamine sulphate 2.5 – 40 mg usual daily dose 1-2x/day dosing start 5 mg qAM/bid 4-8 hours duration
21
ADHD - Psychostimulants
Other Amphetamine Preparations Adderall-XR – 5, 10, 15, 20, 25, 30 mg SR 10-12 hours duration start 5-10 mg qAM; max 30 mg/d may switch Adderall patients to same total daily dose qAM do not cut, crush or chew capsules may sprinkle on non-chewed food
22
ADHD - Psychostimulants
Other Amphetamine Preparations Vyvanse – 10, 20, 30, 40, 50, 60 and 70 mg caps pro-drug, must be metabolized via 1st pass non-oral admin leads to slow activation 3.5 hour half life, but 1-2 hours to onset start mg qAM; max 70 mg/d roughly equivalent to ½ the mg of Adderall indicated for ADHD (6yo+) and binge eating only appropriate if risk of abuse/diversion
23
Adderall, Adderall XR and Vyvanse
24
ADHD - Psychostimulants
Side Effect Management Anorexia adjust timing of dosage – with or after meal adjust amount of dosage ask parents to provide an always-available snack consider medication holidays (hours, days, weeks) monitor weight, consider Remeron for wt gain.
25
ADHD - Psychostimulants
Side Effect Management Insomnia adjust timing of dosage adjust amount of dosage reinforce good sleep hygiene reassess diagnosis (ADHD, comorbidity) consider a small evening stimulant dose (no research substantiation; use with caution) sleep med (melatonin, Benedryl, clonidine, trazodone)
26
ADHD - Psychostimulants
Side Effect Management Irritability reassess diagnosis (ADHD, comorbidity) assess timing of doses- peak?, rebound?, nutrition? adjust dosage or try long acting/short acting form switch stimulants, try/stop drug holidays ?add α-adrenergic agent or antidepressant
27
ADHD - Psychostimulants
Side Effect Management Rebound adjust amount of dosage (up or down, usually down) adjust timing of dosage switch to long-acting stimulant small dose of short-acting stimulant after long-acting reassess diagnosis (ADHD, comorbidity)
28
ADHD - Psychostimulants
Side Effect Management Overfocus (‘hyperfocus’) reduce dosage switch to longer-acting preparation reassess diagnoses (comorbidity, especially OCD, ASD)
29
ADHD - Psychostimulants
Side Effect Management Headache, GI Sx reduce dosage switch to longer-acting preparation assess for migraine, other pathology switch to alternate stimulant hydration, give with food
34
ADHD - Psychostimulants
Magnesium pemoline (Cylert) 18.75, 37.5, 75 mg; 37.5 mg chew Dosage/Schedule single daily dose mg/kg/dose ( mg/dose) do not use due to risk of liver failure
35
ADHD -Adrenergic Agents
originally mediocre antihypertensives clonidine (Catapres), guanfacine (Tenex) effective for impulsivity, impulsive aggression clonidine available as a transdermal patch not effective for hyperactivity/inattention
36
ADHD - -Adrenergic Agents
Clonidine (Catapres) 0.1, 0.2, 0.3 mg tab;0.1/24h, 0.2/24h, 0.3/24h patch Dosage/Schedule mg/dose (0.3mg max/dose in teens) mg/day (1.0mg max/day in teens) (usually 0.05 mg bid to 0.1 mg tid) mg usual starting dose at qhs patch max 0.6mg/24h; ~5d duration in children
37
ADHD - -Adrenergic Agents
Clonidine (Catapres) Advantages effective for impulsivity (and possibly for emotional hyper-reactivity) available as transdermal patch if switching from PO to patch, continue PO for 1-2d, monitoring VS
38
ADHD - -Adrenergic Agents
Clonidine (Catapres) Disadvantages must be slowly titrated up to effective dose while monitoring blood pressure danger of rebound HTN if stopped suddenly shorter half-life for children – esp. the patch baseline and repeat EKG’s
39
ADHD - -Adrenergic Agents
Clonidine (Catapres) Side effects sedation low blood pressure lightheadedness, dizziness dysphoria (feeling bad) headache stomach upset rebound HTN if stopped at high dose local irritation from patch (rotate site)
40
ADHD - -Adrenergic Agents
Guanfacine (Tenex) 1, 2 mg Dosage/Schedule mg/dose mg/day (usually 1 mg qAM to 1 mg tid) mg usual starting dose
41
ADHD - -Adrenergic Agents
Guanfacine (Tenex) Advantages effective for impulsivity (and possibly for emotional hyper-reactivity less sedating than clonidine lowers blood pressure less than clonidine somewhat longer duration than clonidine
42
ADHD - -Adrenergic Agents
Guanfacine (Tenex) Advantages extended release oral prep (Intuniv) Side effects as with clonidine, except for less sedation and less lowering of blood pressure
43
ADHD - Bupropion (Wellbutrin)
Bupropion (Wellbutrin) 75, 100 mg ($) Dosage/Schedule mg initial dose mg day IN DIVIDED DOSES 150 mg max single dose for adolescents 100 mg max single dose for children
44
ADHD - Bupropion (Wellbutrin)
Wellbutrin-SR 100, 150, 200 mg ($$) Dosage/Schedule 100 mg initial dose… single am dose may be sufficient 200 mg max single dose for adolescents 150 mg max single dose for children XL form expensive, not tested in children
45
ADHD - Bupropion (Wellbutrin)
Advantages also treat other conditions such as depression, drug abuse and smoking also available as Wellbutrin-SR effective alternative to stimulants not a controlled substance safe to combine with a stimulant
46
ADHD - Bupropion (Wellbutrin)
Disadvantages risk of seizures (4/1,000) not FDA approved for < 18 years old black box warning for suicide
47
ADHD - Bupropion (Wellbutrin)
Side effects agitation stomach upset headache dizziness constipation dry mouth tremor seizures (rare liver toxicity) tinnitus CAUTION: Wellbutrin = Zyban = bupropion
48
Atomoxetine (Strattera) – 10, 18, 25, 40, 60 mg
ADHD – Atomoxetine Atomoxetine (Strattera) – 10, 18, 25, 40, 60 mg name changed from tomoxetine to avoid confusion with anti-cancer drug tamoxifen hypothesized to act via highly-selective blockade of the presynaptic NE transporter (increases synaptic NE) specific FDA approval for Rx adult and child ADHD
49
ADHD – Atomoxetine Dosage Adult - begin at 40 mg PO qAM x 3d; maximum of 100 mg/day Child – start at 0.5 mg/kg PO qAM x 3d; maximun of 1.4 mg/kg/d adjust dose for hepatic impairment, CYP2D6 competition Initially given bid, but qd dosing equally effective.
50
black box warning for SI can induce mania and psychosis
ADHD – Atomoxetine Side Effects serious: black box warning for SI can induce mania and psychosis HTN, ↑HR, orthostasis, palpitations angioedema and increased narrow-angle glaucoma more common: dry mouth, blurred vision urinary hesitancy/retention abdominal pain, nausea, constipation, dyspepsia insomnia, fatigue impotence, dysmorrhea, ↓libido
51
ADHD – Atomoxetine Advantages Disadvantages
no known addictive potential; not a controlled substance selective inhibitor of NE uptake half-life (T1/2) of 5 hours → QD dosing Disadvantages Expensive (~$1,000/mo), but Wellbutrin is cheap slower onset of positive effects noradrenergic side effect profile
52
Modafinil (Provigil/Sparlon)
a wakefulness-producing non-stimulant drug, highly effective in ADHD less risk of appetite suppression starting dose 100mg qam 300mg max/day, divided bid/tid 200mg average effective daily dose caused Steven-Johnson syndrome in children
53
ADHD - Tricyclic Antidepressants
imipramine (Tofranil) desipramine (Norpramin) nortriptyline (Pamelor) amitriptyline and protriptyline are also available, but the above three tricyclics are preferable based on side effect profile and research base
54
ADHD - Tricyclic Antidepressants
Imipramine/Desipramine Dosage/Schedule mg final dose (2 - 3 mg/kg/day) mg qhs usual starting dose
55
ADHD - Tricyclic Antidepressants
Nortriptyline Dosage/Schedule mg final dose 10 mg qhs usual starting dose
56
ADHD - Tricyclic Antidepressants
Advantages concomitant treatment of comorbid conditions (depression, panic disorder, enuresis) once-twice daily dosing blood levels available
57
ADHD - Tricyclic Antidepressants
Disadvantages cardiac effects reports of sudden death on desipramine subgroup of slow metabolizers delayed onset of action potentially lethal overdose
58
ADHD - Tricyclic Antidepressants
More common side effects sedation orthostatic hypotension lightheadedness, dizziness dry mouth blurred vision constipation elevated heart rate (tachycardia)
59
ADHD - Tricyclic Antidepressants
Less common side effects urinary retention easy sunburn EKG changes (prolonged PR, widened QRS, increased QTc) decreased seizure threshold rash agranulocytosis hypomania/mania
60
ADHD - Tricyclic Antidepressants
Side Effects - Special Considerations obtain a baseline ECG; repeat with each dose increase above 2 mg/kg for imipramine or desipramine, and above 1 mg/kg for nortriptyline; repeat for any cardiac symptoms warning signs: PR interval > 200 ms; QRS > 30% above baseline, or > 120 ms; QTc > 450 ms resting pulse rate > 120; resting systolic BP > 130 or diastolic > 85 risk of sudden death roughly 8 per million per year
61
ADHD - Tricyclic Antidepressants
Side Effects - Special Considerations, continued obtain intermittent CBC, LFT’s blood levels - therapeutic range ng/ml for total of imipramine + desipramine; therapeutic window of ng/ml for nortriptyline taper off gradually to avoid cholinergic rebound potentially dangerous interactions with MAO inhibitors, methylphenidate, and other medications (including over-the-counter medications)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.